- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04351386
Validation Study of the Watch HWA09 and Its Softwares ECG-SW1 and PPG-SW1 for the Detection of Atrial Fibrillation (WEFA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
HWA09 is a wrist-worn watch that enables to record a single-lead ECG similar to the standard lead I configuration, and a photoplethysmogram (PPG).
Primary objective :
To validate the diagnostic performance of the ECG-SW1 software integrated into the HWA09 watch for the automatic identification of atrial fibrillation (AF) compared to a simultaneous 12-lead ECG (hereinafter referred to as the "gold standard" or "reference method").
The algorithm classifies the watch signals into four categories: normal sinus rhythm (RSN), AF, arrhythmia other than AF, or non-interpretable. The latter category includes signals of insufficient quality to be interpreted with confidence.
This classification will be compared to the diagnosis made by three independent, blinded cardiologists based on a 12-lead ECG. The final diagnosis retained will be decided by majority with adjudication by a consensus of 3 to 6 cardiologists. The sensitivity and specificity of the device will then be estimated.
First secondary objectives:
The first secondary objective is to validate the diagnostic performance, compared to a simultaneous 12-lead ECG, of the PPG-SW1 software integrated in the HWA09 watch for the automatic identification of atrial fibrillation (AF) from the photoplethysmography (PPG) signal.
Three independent blinded cardiologists will issue a diagnosis based on the ECG recording of the HWA09 watch. The final diagnosis retained will be decided by majority with adjudication by a consensus of 3 to 6 cardiologists. Sensitivity and specificity will be calculated in relation to the reference ECG.
Second secondary objective:
To evaluate the quality of the single-channel strips measured with the HWA09 watch, as follows:
- Three independent cardiologists, having neither performed the data collection nor read the reference ECG, will independently make a diagnosis based on the HWA09 single-channel strips, blinded to the diagnosis made from the reference ECG. The ECG traces from the watch will be exported in PDF format from the Withings Health Mate application and the final diagnosis will be made by majority with adjudication by a consensus of 3 to 6 cardiologists. The final diagnosis will be compared to the diagnosis made by the cardiologists who read the reference ECG. Sensitivity and specificity will then be calculated.
- The visibility and polarity of ECG waves (i.e. P waves, QRS complex and T waves) will be determined by cardiologists for the single-channel strips recorded with HWA09 and for the lead I of the reference 12-lead ECG. For each of the waves, the agreement on their visibility and polarity (if visible) between the HWA09 and the reference ECG will be calculated.
- The durations of the major intervals of an ECG (i.e., QT interval, QRS complex, and PR interval) will be determined by the cardiologists for the single-channel strips recorded with HWA09 and for the lead I of the reference 12-lead ECG. For each interval (QT, QRS, PR), the difference of duration between the signals from the watch and the reference ECG will be calculated.
- The heart rate will first be determined by cardiologists from each signal of lead I (recorded by the HWA09 watch and the reference ECG) that has been diagnosed as NSR. The difference between the heart rate of the watch and the reference will be calculated. In a second step, the heart rate recorded by the HWA09 watch will be calculated by the Withings software. The difference between the heart rate calculated by the Withings software (from the signal of the watch) and the heart rate determined by the cardiologists (from the lead I of the reference ECG) will also be calculated.
The sponsor will ensure that no cardiologist makes a diagnosis on both a signal from the HWA09 watch and the reference ECG fomr the same patient. The sponsor will centralize diagnostics on the HWA09 and reference ECG signals and perform agreement calculations on the associated pairs.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Ile-de-France
-
Paris, Ile-de-France, France, 75008
- Institut Cœur Paris Centre Turin
-
Paris, Ile-de-France, France, 75015
- Hôpital Européen Georges Pompidou
-
Saint-Denis, Ile-de-France, France, 93200
- Centre Cardiologique du Nord
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Individuals over 18yo
- Individuals who expressed their non-opposition to take part in the study
- Individuals affiliated to a social security system or eligible
Exclusion Criteria:
Vulnerable individuals according to the regulation in force :
- Pregnant, parturient or breastfeeding women
- Individuals deprived of liberty by a court, medical or administrative order
- Individuals under 18yo
- Individuals legally protected or unable to express their non-opposition to take part in
- Individuals unaffiliated to or not beneficiary of a social security system
- Individuals who fit in multiple categories above
- Individuals having refused to take part in the study
- Individuals linguistically or mentally unable to express their non-opposition
- Individuals physically unable to wear a watch
- Individuals with an electrical pacing by a pacemaker
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Atrial Fibrillation (AF)
Patients diagnosed with AF during reference ECG
|
Recording PPG and single-lead ECG signals with the Withings HWA09 and ECG signal for the reference 12-lead ECG
|
Normal Sinus Rhythm (NSR)
Patients with NSR during reference ECG
|
Recording PPG and single-lead ECG signals with the Withings HWA09 and ECG signal for the reference 12-lead ECG
|
Other Arrythmia
Patients diagnosed with an arrhythmia other than AF during the reference ECG
|
Recording PPG and single-lead ECG signals with the Withings HWA09 and ECG signal for the reference 12-lead ECG
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity of the automatic classification in AF by ECG-SW1 of HWA09 single-lead ECG against reference 12-lead ECG
Time Frame: 1 year
|
sensitivity from the 2x2 confusion matrix AF vs 'non-AF'
|
1 year
|
Sensitivity of the automatic classification in NSR by ECG-SW1 of HWA09 single-lead ECG against reference 12-lead ECG
Time Frame: 1 year
|
sensitivity from the 2x2 confusion matrix NSR vs 'non-NSR'
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity of the automatic classification in AF by PPG-SW1 of the HWA09 PPG against reference 12-lead ECG
Time Frame: 1 year
|
sensitivity from the 2x2 confusion matrix AF vs 'non-AF'
|
1 year
|
Sensitivity of the automatic classification in NSR by PPG-SW1 of the HWA09 PPG against reference 12-lead ECG
Time Frame: 1 year
|
sensitivity from the 2x2 confusion matrix NSR vs 'non-NSR'
|
1 year
|
Sensitivity of the cardiologists' classification in AF from the HWA09 ECG
Time Frame: 1 year
|
sensitivity from the 2x2 confusion matrix AF vs 'non-AF'
|
1 year
|
Sensitivity of the cardiologists' classification in SR from the HWA09 ECG
Time Frame: 1 year
|
sensitivity from the 2x2 confusion matrix NSR vs 'non-NSR'
|
1 year
|
Accuracy of the visibility of P-waves of single-lead ECG from HWA09
Time Frame: 1 year
|
(true positives + true negatives)/(sample size) from the 2x2 confusion matrix
|
1 year
|
Accuracy of the positivity of P-waves of single-lead ECG from HWA09
Time Frame: 1 year
|
(true positives + true negatives)/(sample size) from the 2x2 confusion matrix
|
1 year
|
Accuracy of the visibility of QRS-complexes of single-lead ECG from HWA09
Time Frame: 1 year
|
(true positives + true negatives)/(sample size) from the 2x2 confusion matrix
|
1 year
|
Accuracy of the positivity of QRS-complexes of single-lead ECG from HWA09
Time Frame: 1 year
|
(true positives + true negatives)/(sample size) from the 2x2 confusion matrix
|
1 year
|
Accuracy of the visibility of T-waves of single-lead ECG from HWA09
Time Frame: 1 year
|
(true positives + true negatives)/(sample size) from the 2x2 confusion matrix
|
1 year
|
Accuracy of the positivity of T-waves of single-lead ECG from HWA09
Time Frame: 1 year
|
(true positives + true negatives)/(sample size) from the 2x2 confusion matrix
|
1 year
|
RMSE between cardiologist's estimate of heart rate from the HWA09 single-lead ECG and the lead I reference ECG
Time Frame: 1 year
|
Root Mean Squared Error
|
1 year
|
RMSE between cardiologist's estimate of heart rate from the HWA09 single-lead ECG and the heart rate calculated by ECG-SW1
Time Frame: 1 year
|
Root Mean Squared Error
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Julien NAHUM, Centre Cardiologique du Nord
- Study Director: David CAMPO, Withings
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-A01476-51
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
Beijing Anzhen HospitalJohnson & Johnson; Heart Health Research CenterNot yet recruitingParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation
-
Maastricht UniversityRadboud University Medical Center; Maastricht University Medical CenterRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Atrial Fibrillation ParoxysmalNetherlands
Clinical Trials on AF Detection
-
WithingsClinactCompletedHypertension | Atrial Fibrillation | Valvular Heart DiseaseFrance
-
WithingsClinactCompletedAtrial Fibrillation | Arrythmia, CardiacFrance
-
MicrolifeCompletedAtrial FibrillationUnited States
-
Yale UniversityNational Institute on Drug Abuse (NIDA)CompletedDrug Use Disorders | Psychiatric Diagnosis | Diagnosis, Dual (Psychiatry)United States
-
Neil SulkeSuspended
-
Hospital Clinic of BarcelonaInstitut d'Investigacions Biomèdiques August Pi i Sunyer; University of BarcelonaCompletedAtrial FibrillationSpain
-
Medtronic Cardiac Rhythm and Heart FailureCompletedAtrial FibrillationSaudi Arabia, Italy, United Kingdom, United States, Slovakia, Hungary, South Africa
-
Keimyung University Dongsan Medical CenterAbbottUnknownAtrial FibrillationKorea, Republic of
-
NestléCompletedSubarachnoid Hemorrhage, Aneurysmal | Injuries, Acute Brain | Severe Trauma Brain Injury (sTBI)Switzerland
-
Ravi RanjanBiosense Webster, Inc.RecruitingAtrial FibrillationUnited States